NASDAQ:AUTL
Autolus Therapeutics plc Stock News
$4.39
+0.320 (+7.86%)
At Close: May 17, 2024
CAR-T Pipeline Insights Report 2020: Comprehensive Insights on 250+ Companies and Pipeline Drugs - ResearchAndMarkets.com
12:00am, Wednesday, 23'rd Sep 2020
The
Curis (NASDAQ:CRIS) and Autolus Therapeutics (NASDAQ:AUTL) Critical Comparison
02:28am, Sunday, 20'th Sep 2020
Curis (NASDAQ:CRIS) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their
Autolus Therapeutics Plc (AUTL) Investor Presentation - Slideshow
02:21pm, Friday, 11'th Sep 2020
The following slide deck was published by Autolus Therapeutics plc in conjunction with this event.
Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q2 2020 Results - Earnings Call Transcript
07:37am, Sunday, 09'th Aug 2020
Autolus Therapeutics PLC (NASDAQ:AUTL) Q2 2020 Earnings Conference Call August 06, 2020, 08:30 ET Company Participants Lucinda Crabtree - VP, IR & Corporate Communications Christian Itin - Chairma
Autolus Therapeutics Reports Second Quarter 2020 Financial Results and Operational Progress
11:00am, Thursday, 06'th Aug 2020
\- Conference call to be held on August 6, 2020 at 8:30 am EDT/1:30 pm BST -LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical compa
J.P. Morgan: These 2 Healthcare Stocks Are Must-Watch Names
02:05pm, Wednesday, 05'th Aug 2020
Marching forward together, the previous decade saw equities and bonds rally right alongside each other. At the same time, there was a negative correlation of daily returns, limiting portfolio volatili
Autolus announces changes to its Board and Management Team
11:00am, Tuesday, 04'th Aug 2020
Dr. Jay T. Backstrom appointed to board of directorsLONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-gener
Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6
11:00am, Thursday, 30'th Jul 2020
LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t
Hedge Funds Are Buying Autolus Therapeutics plc (AUTL)
08:39pm, Thursday, 02'nd Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
William Blair Remains a Buy on Autolus Therapeutics (AUTL) - Markets
09:52am, Friday, 26'th Jun 2020
In a report released yesterday, Matt Phipps from William Blair reiterated a Buy rating on Autolus Therapeutics (AUTL – Research
2020 Insights into the Global Multiple Myeloma Market and Competitive Landscape - ResearchAndMarkets.com
12:00am, Friday, 26'th Jun 2020
The
Autolus Therapeutics (AUTL) Gets a Buy Rating from Needham - Markets
04:51pm, Thursday, 25'th Jun 2020
Needham analyst Chad Messer maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price
Autolus Therapeutics (AUTL) Received its Third Buy in a Row - Markets
03:22pm, Thursday, 25'th Jun 2020
After William Blair and Needham gave Autolus Therapeutics (NASDAQ: AUTL) a Buy rating last month, the company received another Buy,
Moving Average Crossover Alert: Autolus Therapeutics
01:32pm, Wednesday, 24'th Jun 2020
Autolus Therapeutics plc (AUTL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting
11:00am, Monday, 22'nd Jun 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced preclinical data related to AUTO5 in T cell lymphom
